In 2008, 25 percent of all drugs approved by the U.S. Food and Drug Administration were considered specialty drugs—what the FDA calls new molecular entities—and that number only has gone up since. Now, more than 50 percent of all drugs approved by the FDA are specialty drugs.
And, according to Reuters, the top 3 selling pharmaceuticals in 2014 will be specialty or oncology drugs, topping mainstays such as Lipitor, Plavix and Advair.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
